Haematologica, Vol 93, Issue 3, 471-472 doi:10.3324/haematol.12013
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bodet-Milin, C.
Right arrow Articles by Le Gouill, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bodet-Milin, C.
Right arrow Articles by Le Gouill, S.

Lymphoproliferative Disorders

Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma

Caroline Bodet-Milin1, Françoise Kraeber-Bodéré1, Philippe Moreau2, Loïc Campion3, Benoît Dupas4, Steven Le Gouill5,

1 Nuclear Medicine Department, University Hospital, Nantes
2 Histopathology Department, University Hospital, Nantes
3 Statistics Department, René Gauducheau Cancer Centre, Nantes
4 Radiology Department, University Hospital, Nantes
5 Hematology Department, University Hospital, Nantes, France

Correspondence: Steven Le Gouill, Haematology Department, University Hospital, Place Alexis Ricordeau, 44093 Nantes cedex 1, France. Phone: international +33.02.40083263. Fax: international +33.02.40083250. E-mail: steven.legouill{at}chu-nantes.fr

Positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) has been successfully evaluated in the management of non-Hodgkin’s lymphoma (NHL).1–3 Histological transformation (HT) of indolent lymphoma is a dramatic event that occurs in 5–10% of the patients and carries a dismal prognosis.4,5 Previous studies prove that indolent lymphoma entities show a lower FDG uptake when compared with aggressive lymphomas.6–8 We therefore postulated that FDG-PET/CT identifies aggressive transformation sites and can guide biopsies.

Key words: FDG-PET/CT, lymphoma, biopsy, histological transformation.




This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
C. G. Cronin, R. Swords, M. T. Truong, C. Viswanathan, E. Rohren, F. J. Giles, M. O'Dwyer, and J. F. Bruzzi
Clinical Utility of PET/CT in Lymphoma
Am. J. Roentgenol., January 1, 2010; 194(1): W91 - W103.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Delbeke, S. Stroobants, E. de Kerviler, C. Gisselbrecht, M. Meignan, and P. S. Conti
Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma
Oncologist, October 1, 2009; 14(suppl_2): 30 - 40.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Ben-Haim and P. Ell
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
J. Nucl. Med., January 1, 2009; 50(1): 88 - 99.
[Abstract] [Full Text] [PDF]